Literature DB >> 14592342

Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome.

Arthur S Walters1, Cheryl LeBrocq, Anjana Dhar, Wayne Hening, Ray Rosen, Richard P Allen, Claudia Trenkwalder.   

Abstract

BACKGROUND: There is a need for an easily administered instrument which can be applied to all patients with restless legs syndrome (RLS) to measure disease severity for clinical assessment, research, or therapeutic trials. The pathophysiology of RLS is not clear and no objective measure so far devised can apply to all patients or accurately reflect severity. Moreover, RLS is primarily a subjective disorder. Therefore, a subjective scale is at present the optimal instrument to meet this need.
METHODS: Twenty centers from six countries participated in an initial reliability and validation study of a rating scale for the severity of RLS designed by the International RLS study group (IRLSSG). A ten-question scale was developed on the basis of repeated expert evaluation of potential items. This scale, the IRLSSG rating scale (IRLS), was administered to 196 RLS patients, most on some medication, and 209 control subjects.
RESULTS: The IRLS was found to have high levels of internal consistency, inter-examiner reliability, test-retest reliability over a 2-4 week period, and convergent validity. It also demonstrated criterion validity when tested against the current criterion of a clinical global impression and readily discriminated patient from control groups. The scale was dominated by a single severity factor that explained at least 59% of the pooled item variance.
CONCLUSIONS: This scale meets performance criteria for a brief, patient completed instrument that can be used to assess RLS severity for purposes of clinical assessment, research, or therapeutic trials. It supports a finding that RLS is a relatively uniform disorder in which the severity of the basic symptoms is strongly related to their impact on the patient's life. In future studies, the IRLS should be tested against objective measures of RLS severity and its sensitivity should be studied as RLS severity is systematically manipulated by therapeutic interventions.

Entities:  

Mesh:

Year:  2003        PMID: 14592342     DOI: 10.1016/s1389-9457(02)00258-7

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


  353 in total

Review 1.  Role of dopamine receptor agonists in the treatment of restless legs syndrome.

Authors:  Svenja Happe; Claudia Trenkwalder
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 2.  Restless legs syndrome: a comprehensive overview on its epidemiology, risk factors, and treatment.

Authors:  Paul Yeh; Arthur S Walters; John W Tsuang
Journal:  Sleep Breath       Date:  2011-10-26       Impact factor: 2.816

3.  Investigation of unmedicated early onset restless legs syndrome by voxel-based morphometry, T2 relaxometry, and functional MR imaging during the night-time hours.

Authors:  P N Margariti; L G Astrakas; S G Tsouli; G M Hadjigeorgiou; S Konitsiotis; M I Argyropoulou
Journal:  AJNR Am J Neuroradiol       Date:  2011-12-15       Impact factor: 3.825

4.  Use of near-infrared light to reduce symptoms associated with restless legs syndrome in a woman: a case report.

Authors:  Ulrike H Mitchell
Journal:  J Med Case Rep       Date:  2010-08-23

Review 5.  Restless legs syndrome: pathophysiology, clinical presentation and management.

Authors:  Claudia Trenkwalder; Walter Paulus
Journal:  Nat Rev Neurol       Date:  2010-06       Impact factor: 42.937

6.  Restless legs and substantia nigra hypoechogenicity are common features in Friedreich's ataxia.

Authors:  Matthis Synofzik; Jana Godau; Tobias Lindig; Ludger Schöls; Daniela Berg
Journal:  Cerebellum       Date:  2011-03       Impact factor: 3.847

7.  Restless legs syndrome: diagnostic assessment and the advantages and risks of dopaminergic treatment.

Authors:  Birgit Högl; Walter Paulus; Peter Clarenbach; Claudia Trenkwalder
Journal:  J Neurol       Date:  2006-08       Impact factor: 4.849

8.  A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome.

Authors:  Clete A Kushida; Arthur S Walters; Philip Becker; Stephen G Thein; A Thomas Perkins; Thomas Roth; Daniel Canafax; Ronald W Barrett
Journal:  Sleep       Date:  2009-02       Impact factor: 5.849

9.  Impact of restless legs syndrome in patients with inflammatory bowel disease on sleep, fatigue, and quality of life.

Authors:  Katharina A Schindlbeck; Janek Becker; Felix Berger; Arne Mehl; Charlotte Rewitzer; Sarah Geffe; Peter M Koch; Jan C Preiß; Britta Siegmund; Jochen Maul; Frank Marzinzik
Journal:  Int J Colorectal Dis       Date:  2016-10-18       Impact factor: 2.571

10.  Restless Legs Syndrome and Depression: Effect Mediation by Disturbed Sleep and Periodic Limb Movements.

Authors:  Brian B Koo; Terri Blackwell; Hochang B Lee; Katie L Stone; Elan D Louis; Susan Redline
Journal:  Am J Geriatr Psychiatry       Date:  2016-04-27       Impact factor: 4.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.